Bast D J, Banerjee L, Clark C, Read R J, Brunton J L
The Samuel Lunenfeld Research Institute, Mount Sinai Hospital; Department of Molecular and Medical Genetics, University of Toronto, Toronto, Canada.
Mol Microbiol. 1999 Jun;32(5):953-60. doi: 10.1046/j.1365-2958.1999.01405.x.
The Verotoxin 1 (VT1) B subunit binds to the glycosphingolipid receptor globotriaosylceramide (Gb3). Receptor-binding specificity is associated with the terminally linked Galalpha(1-4) Galbeta disaccharide sequence of the receptor. Recently, three globotriose (Galalpha[1-4] Galbeta [1-4] Glcbeta) binding sites per B-subunit monomer were identified by crystallography. Two of these sites (sites I and II) are located adjacent to phenylalanine-30. Site I was originally predicted as a potential Gb3 binding site on the basis of sequence conservation, and site II was additionally predicted based on computer modelling and receptor docking. The third (site III) was also identified by crystallography and is located at the N-terminal end of the alpha-helix. To determine the biological significance of sites II and III, and to support our previous findings of the significance of site I, we examined the binding properties and cytotoxicity of VT1 mutants designed to block Gb3 binding at each site selectively. The Scatchard analysis of saturation-binding data for each mutant revealed that only the amino acid substitutions predicted to affect site I (D-17E) or site II (G-62T) caused reductions in the binding affinity and capacity of VT1 for Gb3. Similarly, those mutations at sites I and II also caused significant reductions in both Vero and MRC-5 cell cytotoxicity (by seven and five logs, respectively, for G-62T and by four and two logs, respectively, for D-17E). In contrast, the substitution of alanine for W-34 at site III did not reduce the high-affinity binding of the B subunit, despite causing a fourfold reduction in the receptor-binding capacity. The corresponding mutant W-34A holotoxin had a two-log reduction in cytotoxicity on Vero cells and no statistically significant reduction on MRC-5 cells. We conclude that the high-affinity receptor binding most relevant for cell cytotoxicity occurs at sites I and II. In contrast, site III appears to mediate the recognition of additional Gb3 receptor epitopes but with lower affinity. Our results support the significance of the indole ring of W-34 for binding at this site.
志贺毒素1(VT1)的B亚基与糖鞘脂受体球三糖神经酰胺(Gb3)结合。受体结合特异性与受体末端连接的Galα(1-4)Galβ二糖序列相关。最近,通过晶体学确定每个B亚基单体有三个球三糖(Galα[1-4]Galβ[1-4]Glcβ)结合位点。其中两个位点(位点I和位点II)位于苯丙氨酸-30附近。位点I最初基于序列保守性被预测为潜在的Gb3结合位点,位点II则是基于计算机建模和受体对接另外预测出来的。第三个位点(位点III)也是通过晶体学确定的,位于α螺旋的N末端。为了确定位点II和位点III的生物学意义,并支持我们之前关于位点I重要性的发现,我们研究了旨在选择性阻断每个位点Gb3结合的VT1突变体的结合特性和细胞毒性。对每个突变体的饱和结合数据进行Scatchard分析表明,只有预测会影响位点I(D-17E)或位点II(G-62T)的氨基酸取代导致VT1对Gb3的结合亲和力和结合能力降低。同样,位点I和位点II的那些突变也导致Vero细胞和MRC-5细胞的细胞毒性显著降低(G-62T分别降低7个和5个对数级,D-17E分别降低4个和2个对数级)。相比之下,位点III处用丙氨酸取代W-34并没有降低B亚基的高亲和力结合,尽管受体结合能力降低了四倍。相应的突变体W-34A全毒素对Vero细胞的细胞毒性降低了两个对数级,对MRC-5细胞没有统计学上的显著降低。我们得出结论,与细胞毒性最相关的高亲和力受体结合发生在位点I和位点II。相比之下,位点III似乎介导了对其他Gb3受体表位的识别,但亲和力较低。我们的结果支持W-34的吲哚环在此位点结合中的重要性。